Skip to content

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Cytokinetics logo
CytokineticsCYTK
4.2×-1.8×
PTC Therapeutics logo
PTC TherapeuticsPTCT
2.4×-1.5×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
7.1×+1.0×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
19.9×-0.4×
Viking Therapeutics logo
Viking TherapeuticsVKTX
5.7×-38.5×

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$3.96B+61.3%
Enterprise value$3.93B+63.5%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×

Where this comes from

Calculated from Edgewise Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s current ratio?
Edgewise Therapeutics, Inc. (EWTX) reported current ratio of 22.6× in Q1 2026.
How has Edgewise Therapeutics, Inc.'s current ratio changed year-over-year?
Edgewise Therapeutics, Inc.'s current ratio increased by 7.7% year-over-year, from 21× to 22.6×.
What is the long-term trend for Edgewise Therapeutics, Inc.'s current ratio?
Over 5 years (2020 to 2025), Edgewise Therapeutics, Inc.'s current ratio has grown at a -7.8% compound annual growth rate (CAGR), from 29.9× to 19.9×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.